<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482817</url>
  </required_header>
  <id_info>
    <org_study_id>Ze117-1-2017-01</org_study_id>
    <nct_id>NCT03482817</nct_id>
  </id_info>
  <brief_title>Drug Cocktail Interaction Study of St. John's Wort Dry Extract Ze 117</brief_title>
  <official_title>Drug Cocktail Interaction Study to Investigate the Effect of St. John's Wort Dry Extract Ze 117 on Several Cytochrome P450 Enzymes and on Transporter P-Glycoprotein in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max Zeller Soehne AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Max Zeller Soehne AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Study evaluates the Effect of St. John's Wort dry Extract Ze 117 on Several Cytochrome
      P450 Enzymes and on Transporter P-Glycoprotein in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current data indicate that St. John's wort preparations may induce hepatic cytochrome P450
      enzymes and transport proteins. This can result in drug interactions.

      The study design is standard for DDI studies and is based on the regulatory guidance of the
      Food and Drug Administration (FDA) and of the European Medicines Agency (EMA).

      A cocktail approach involving the administration of multiple cytochrome P450 (CYP)- or
      P-glycoprotein (P-gp)-specific probe drugs is used to simultaneously assess the activities of
      these enzymes and the transporter P-gp.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">June 23, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open-label, non-randomized, single-sequence study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Plasma concentration versus time curve (AUC0-t)</measure>
    <time_frame>72 hours</time_frame>
    <description>Pharmacokinetic Parameter AUC0-t (mg*h/L) of the probe drugs will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the Plasma concentration versus time curve (AUC0-inf)</measure>
    <time_frame>72 hours</time_frame>
    <description>Pharmacokinetic parameter (mg*h/L) of the probe drugs and their metabolites will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>72 hours</time_frame>
    <description>Pharmacokinetic Parameter (ng/ml) of the probe drugs and their metabolites will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (Ke)</measure>
    <time_frame>72 hours</time_frame>
    <description>Pharmacokinetic Parameter (h^−1) of the probe drugs and their metabolites will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half life (t1/2)</measure>
    <time_frame>72 hours</time_frame>
    <description>Pharmacokinetic Parameter (h) of the probe drugs and their metabolites will be determined.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Drug Interaction Study</condition>
  <arm_group>
    <arm_group_label>Probe drug cocktail / Ze 117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-sequence, Probe drug cocktail alone and in combination with Ze 117.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ze 117</intervention_name>
    <description>Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.</description>
    <arm_group_label>Probe drug cocktail / Ze 117</arm_group_label>
    <other_name>St. John's wort dry extract Ze 117</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probe drug cocktail</intervention_name>
    <description>Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.</description>
    <arm_group_label>Probe drug cocktail / Ze 117</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  Caucasian male or female subjects aged between ≥18 and ≤55years

          -  Physically and mentally healthy

          -  BMI between ≥19 and ≤29 kg/m2, and body weight ≤90 kg

          -  Non-smoker

          -  If female, the pregnancy test at screening and at admission must be negative

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to study drugs

          -  history of, any clinically significant diseases

          -  Positive test of hepatitis B, hepatitis C or HIV Screening

          -  Known photohypersensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Caucasian</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lissy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neu-Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

